U.S. Markets close in 1 hr 18 mins

BioLine Rx Ltd (BLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.00+0.04 (+3.96%)
As of 2:34PM EDT. Market open.
People also watch
  • This really encouraging news & speaks to true value of where large holder believes value should be.

  • It's about to explode...
  • Get rid of the moron CEO Phil and the share price will be $1.25
  • BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in the Company to 24.9%. The sale is expected to close on or about July 31, 2017, subject to satisfaction of customary closing conditions.

    BVF's new investment is priced at $1.13 per unit. Each unit consists of 1 ordinary share, 0.35 of a Series A warrant, and 0.35 of a Series B warrant. The Series A warrants have an exercise price of $2.00 per ordinary share and a 4-year term. The Series B warrants have an exercise price of $4.00 per ordinary share and a 4-year term. The securities are being offered pursuant to a prospectus as a registered direct placement.
  • MicroCap Alert to BLRX shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric.
    Each system sells for about $300,000. Demand for CETY HRS is very strong.
    CETY just expanded Europe sales and service office in high demand market
    CETY immediately announced first new sale in Europe
    CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.

    Expect substantial sales orders to flow soon after conference
    CETY 1017 target: $.15 to $.20



    Clean Energy Technologies, Inc. Delivering Low Cost, Emission Free Power with its Heat Recovery Solutions Clean Cycle™ Generator acquired from General Electric International, Inc.
    COSTA MESA, Calif., March 1, 2016 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY), recently...
  • People must understand this - it has deep value. You are getting a cancer treatment going into phase 3 and company valued less than $100 million. It will go to $2-$3 before Nov. or before if they announce some interim analysis
  • May be up because of this article

    BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy
    BioLineRx might be one of the best biotech values in the stock market, as it has a promising pipeline, a cash-rich balance sheet and a low burn rate. Don't be p
  • something is up ...very heavy volume ...
  • Hold tight because we're taking off
  • If they get rid of Phil, the share price would rise by at least .20

    Advisory board and CMO are running the trials, BLRX self proclaimed, they don't need cash until 2020

    What the hell is Phil doing?
  • Will close at .79
  • .06 From breaking a new record low
    Phil has got to go!
  • Nothing is keeping this POS from tanking to .25
    This efin management team is looking at a possibility of another failed trial

    If Novartis bails, BLRX is toast
  • nothing happens after shareholders meeting
  • This moron of of a CEO is going to get BLRX delisted
  • You suk Phil,K girl was better and she suked
  • Been holding BLRX for sometime but it seems nothing can make this stock move up; still awaiting patiently....urghhh
  • You suk Phil
  • IGXT (MC $46 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .GLTA

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL

    Intelgenx (IGXT)

    MarketCap $46 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.70

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017


    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

  • Phil the efin moron CEO will have us trading in the pink sheets by years end. K girl was horrible, this f-in moron is a waste of a load.